Spruce Biosciences, Inc. Additional Paid in Capital, Common Stock
Spruce Biosciences, Inc. (SPRB) had Additional Paid in Capital, Common Stock of $401.46 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AdditionalPaidInCapitalCommonStock · last filed 2026-08-12
- 2026-06-30: Additional Paid in Capital, Common Stock $401.46M.
- 2026-03-31: Additional Paid in Capital, Common Stock $336.15M.
- 2025-12-31: Additional Paid in Capital, Common Stock $331.75M.
- 2025-09-30: Additional Paid in Capital, Common Stock $279.97M.
| Period end | Additional Paid in Capital, Common Stock | Additional Paid in Capital, Common Stock as first filed |
|---|---|---|
| 2026-06-30 | $401.46M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $336.15M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $331.75M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $279.97M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $279.56M 10-Q · filed 2025-08-14 | |
| 2025-03-31 | $279.63M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $279.09M 10-K · filed 2026-03-09 | $279.08M 10-K · filed 2025-04-15 |
| 2024-09-30 | $278.34M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $277.20M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $275.48M 10-Q · filed 2024-05-13 | |
| 2023-12-31 | $273.74M 10-K · filed 2025-04-15 | |
| 2023-09-30 | $272.66M 10-Q · filed 2023-11-13 | |
| 2023-06-30 | $271.54M 10-Q · filed 2023-08-14 | |
| 2023-03-31 | $270.29M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $218.35M 10-K · filed 2024-03-18 | |
| 2022-09-30 | $217.51M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $216.73M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $215.83M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $214.69M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $213.68M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $212.63M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $211.45M 10-Q · filed 2021-05-12 | |
| 2020-12-31 | $210.27M 10-K · filed 2022-03-14 | |
| 2020-09-30 | $1.06M 10-Q · filed 2020-11-18 | |
| 2019-12-31 | $664.00K 10-K · filed 2021-03-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |